Advancing Precision Medicine in High-Risk Breast Cancer: BRCA Mutations, Triple-Negative, and HR+/HER2– Subtypes - Episode 6

KN-522: Clinical Implications and Insights Into Clinical Practice

,

Panelists highlight the KN-522 study and discuss how updated KEYNOTE-522 data influence their selection of patients for pembrolizumab-containing regimens, focusing on factors that guide the decision to recommend immunotherapy and how to approach patients with borderline indications.

EP. 1: NATALEE and monarchE: Clinical Data Review and Insights Into Treating High-Risk HR+/HER2_ Early-Stage Breast Cancer
EP. 2: Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data
EP. 3: BRCA Testing in Early-Stage and Metastatic Breast Cancer
EP. 4: OlympiA: Data Updates From SABCS 2024
EP. 5: Role of PARP Inhibitors in Somatic BRCA Mutations and Data Update for PARP Inhibitors
Now Viewing
EP. 6: KN-522: Clinical Implications and Insights Into Clinical Practice
EP. 7: Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
EP. 8: SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC

Video content above is prompted by the following:

  1. Dr. Shatsky please highlight the KN-522 study briefly before moving into discussion>>transition to>>Dr Shatsky asks Dr Degen:Based on updated KEYNOTE-522 data, how do you select patients for pembrolizumab-containing regimens?
    1. What factors influence your decision to recommend immunotherapy?
    2. How do you approach patients with borderline indications?